The US-federal agency, Food and Drug Administration (FDA) has the approval of new medicine for migraine treatment. Reyvow (lasmitidan) tab is helpful for short-term effects in migraine patients. It doesn’t prevent long-lasting effects and is more of a preventive treatment plant for migraine and aura in adult migraine patients.
This is another drug from Indianapolis-based Eli Lilly and Co. that gets approval from the FDA. This medicine named RREYVOW helps the patients of acute migraine.
The recommended controlled substance classification for
REYVOW is currently under review by the Drug Enforcement Administration for classification under controlled substances list. It will take no more than 90 days after the FRA approval to available to patients.
REYVOW is launched after a series of research
Nick Kozauer, the acting deputy director of the Division of Neurology Products and M.D. in the Center for Drug Evaluation and Research, FDA finds REYVOW a good treatment plan for migraine. Migraine is a type of headache that affects one in every seven adults in the USA. It feels like an intense pain that only shows up in one part of the head. Its common symptoms include light and sound sensitivity, nausea, and vomiting. Moreover one most famous sign that may or may now show up with a migraine is aura.
Also read- Easy Home Remedies For Migraine
An aura feels like a person is watching zig-zag lines, rushing flashlights, or a brief loss of vision. If someone is suffering from both aura, any bright or flashing light, hormonal change, stress, sleeping habits, and diet all can trigger a migraine. Unfortunately, migraine is more common in women than in men.
To test the effectiveness of REYVOW, two randomized, placebo-controlled, and double-blind trials were preceded. Both these studies analyzed the effects of REYWO on 3,177 adult patients with a history of migraine, with and without aura. There were promising effects in patients regarding migraine symptoms and pain within two hours of taking REYVOW.
Is it completely safe to use?
This approval represents a new class of acute migraine treatment that gets FDA approval in the last two decades. It sets new expectations in migraine care, which targets to provide migraine-free life for all those who are having it.
The studies on Reyvow show that it has effects on the central nervous system (CNS), which may show up in the form of depression, sedation or dizziness. That is why one has to be careful while using Reyvow. Do not use it in combination with other CNS depressants. Also, avoid taking it with alcohol.
The common side effects that may show up with Reyvow usage include fatigue, wooziness, drowsy feeling, and burning or itchiness of the skin. That is why researchers advise patients not to drive a vehicle or operate any machinery if they are taking Reyvow. The first eight hours after taking Reyvow are crucial and these effects gradually fade after 8 hours.
Food and Drug Administration (FDA) aims to provide advancements in health and control public health threats by using effective and safe measures. It has now given approval to Reyvow and only in a few months, it would be available at all leading pharmacies.